Telix Pharmaceuticals has partnered with Subtle Medical to integrate SubtlePET™ software with Telix's Illuccix® product, aiming to enhance PET imaging.
SubtlePET™ utilizes AI-powered deep-learning algorithms to expedite PET scanning processes, reducing scan times by up to 75% without compromising image quality. This technology improves patient comfort, reduces wait times, and streamlines the patient journey through medical facilities.
The integration of SubtlePET™ into existing imaging workflows is seamless and adaptable across various scanner models.
Telix CEO, Kevin Richardson, expressed excitement about the partnership and its potential to strengthen Telix's position in the market.
The collaboration between Telix and Subtle Medical is a significant milestone in medical imaging, particularly in prostate cancer diagnostics. It sets new standards for accuracy, reliability, and operational excellence in PSMA-PET imaging.
The partnership aligns with the trend of incorporating AI into healthcare solutions to enhance diagnostic processes and patient experiences.
Telix Pharmaceuticals, headquartered in Melbourne, Australia, is focused on developing and commercializing diagnostic and therapeutic radiopharmaceuticals. The partnership with Subtle Medical enhances Telix's product offerings and aligns with industry trends towards digital transformation in healthcare. Telix's proactive approach positions it favorably for sustained growth and success in the evolving landscape of biopharmaceuticals and medical imaging.